Introduction
A lot has happened at ChemoCentryx (NASDAQ:CCXI) since my first report back in November 2017.
Following the release of the ADVOCATE trial top-line results in late November 2019, ChemoCentryx share price more than quadrupled and interest in the company spiked.
Analysts following the company have PT ranging from $58 to $102. Moreover, CCXI has seen an increase in institutional ownership and represents a top 5 position for Consonance Capital Management, Cormorant Asset Management, and RA Capital Management. Such specialist funds' support is nice to see.
It is an opportune time to update